RTI Surgical reaches global milestone of providing 8 million biologic implants with zero confirmed incidence of implant-associated infection

89
RTI Surgical has provided over eight million biologic implants processed through the company’s proprietary sterilisation processes with zero confirmed incidence of implant-associated infection

RTI Surgical celebrates a significant global milestone: providing more than eight million biologic implants processed through the company’s proprietary sterilisation processes with zero confirmed incidence of implant-associated infection. In 2017 alone, RTI distributed more than 600,000 biologic implants—helping surgeons serve patients in nearly 50 countries.

RTI Surgical—also this year celebrating its 20th anniversary of delivering surgical implants —was the first to introduce tissue-specific validated sterilisation processes: the BioCleanse Tissue Sterilisation Process, the Cancelle SP DBM Sterilisation Process and the Tutoplast Tissue Sterilisation Process. It was also the first company to offer precision-shaped bone implants and assembled technologies.

“RTI Surgical continues to raise the bar as a trusted provider of patient-centered biologic solutions with a proven track record for advancing science, safety and innovation,” says Peter Indelicato (Orthopaedics and Sports Surgery division, Department of Orthopaedics and Rehabilitation Sports Medicine, University of Florida, Gainesville, USA). “RTI was instrumental in developing groundbreaking sterilisation technology with proven effectiveness and safety, such as BioCleanse, and continues to drive innovation today with its portfolio of biologic implants. As the former head team physician for the University of Florida Gator football team, I often relied on RTI implants to help restore our athletes to health.”

Camille Farhat, president and CEO, RTI Surgical, comments, “For 20 years, RTI has led the way in tissue safety for biologic implants in our industry, always keeping the patient in mind. Our commitment to tissue safety is evident by our redundant safeguards and proprietary, validated sterilisation processes, allowing us to achieve more than eight million biologic implants with zero confirmed incidence of implant-associated infection. We celebrate these milestones in honour of the healthcare professionals and patients we serve globally and with appreciation for the gifts of life that make such healing and restoration possible.”

RTI’s tissue-based implants are used in a variety of surgical procedures, including anterior cruciate ligament reconstruction, meniscus transplantation, and fracture repair.

(Visited 41 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here